GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve (IST:ANGEN) » Definitions » Capex-to-Revenue

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) Capex-to-Revenue : 0.44 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Capital Expenditure for the three months ended in Sep. 2023 was ₺-21.77 Mil. Its Revenue for the three months ended in Sep. 2023 was ₺49.79 Mil.

Hence, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Capex-to-Revenue for the three months ended in Sep. 2023 was 0.44.


Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Capex-to-Revenue Historical Data

The historical data trend for Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Capex-to-Revenue Chart

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Revenue
- - 0.17 0.19 0.35

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Quarterly Data
Dec18 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.89 0.75 0.58 0.44

Competitive Comparison of Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Capex-to-Revenue

For the Medical Devices subindustry, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Capex-to-Revenue falls into.



Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Capex-to-Revenue Calculation

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Capex-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-94.114) / 268.817
=0.35

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Capex-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-21.771) / 49.79
=0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve  (IST:ANGEN) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) Business Description

Traded in Other Exchanges
N/A
Address
Egitim Mah. Kasap Ismail, Sk. No:10 D:23, Kadikoy, Istanbul, TUR, 34722
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve Ticaret AS is an international biotechnology company. It is engaged in designing, developing, and manufacturing Real-Time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments. It also manufactures NA Extraction kits, Microbiology kits, Genetic Disorders kits, Panel kits, Sequencing kits, Food Testing kits.

Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirmenayi Ve (IST:ANGEN) Headlines

No Headlines